Abstract：
OBJECTIVE: The study investigates cryotherapy\'s efficacy in mitigating Chemotherapy-induced peripheral neuropathy (CIPN), an adverse effect of chemotherapy that often leads to dosage reduction or treatment discontinuation.
METHODS: The study was registered with PROSPERO (CRD42023428936). A literature search was conducted using the PubMed, Embase, and Cochrane Library databases. Randomized and nonrandomized controlled trials that investigated the effects of cryotherapy on CIPN were included for systematic review and meta-analysis. The primary outcome for prevention was the incidence of CIPN.
RESULTS: We identified 17 trials involving 2,851 patients. In total, 11 trials compared the incidence of CIPN between cryotherapy and control groups. Significant differences in the incidence of CIPN at the midpoint and end of chemotherapy were observed, with risk ratios (RRs) of 0.23 (95% confidence interval [CI] = 0.13 to 0.43) and 0.54 (95% CI = 0.33 to 0.88), respectively. Cryotherapy also significantly reduced the incidence of sensory CIPN, with an RR of 0.67 (95% CI = 0.49 to 0.92). Additionally, cryotherapy demonstrated a significant reduction in the incidence of CIPN in patients with gynecological cancers (RR = 0.24, 95% CI = 0.14 to 0.41). Significantly favorable global quality of life scores following chemotherapy (standardized mean difference = 1.43; 95% CI = 0.50 to 2.36) and relieved neuropathic symptoms were found with cryotherapy.
CONCLUSIONS: Cryotherapy demonstrates a pronounced preventive effect against the development of CIPN, providing substantial symptomatic relief and quality of life improvements for patients undergoing chemotherapy. The administration of cryotherapy through the use of frozen gloves and socks, or continuous-flow cooling systems, optimally initiated 15 min prior to and concluded 15 min following chemotherapy, is recommended for achieving maximum therapeutic efficacy.
METHODS: The study was registered with PROSPERO (CRD42023428936). A literature search was conducted using the PubMed, Embase, and Cochrane Library databases. Randomized and nonrandomized controlled trials that investigated the effects of cryotherapy on CIPN were included for systematic review and meta-analysis. The primary outcome for prevention was the incidence of CIPN.
RESULTS: We identified 17 trials involving 2,851 patients. In total, 11 trials compared the incidence of CIPN between cryotherapy and control groups. Significant differences in the incidence of CIPN at the midpoint and end of chemotherapy were observed, with risk ratios (RRs) of 0.23 (95% confidence interval [CI] = 0.13 to 0.43) and 0.54 (95% CI = 0.33 to 0.88), respectively. Cryotherapy also significantly reduced the incidence of sensory CIPN, with an RR of 0.67 (95% CI = 0.49 to 0.92). Additionally, cryotherapy demonstrated a significant reduction in the incidence of CIPN in patients with gynecological cancers (RR = 0.24, 95% CI = 0.14 to 0.41). Significantly favorable global quality of life scores following chemotherapy (standardized mean difference = 1.43; 95% CI = 0.50 to 2.36) and relieved neuropathic symptoms were found with cryotherapy.
CONCLUSIONS: Cryotherapy demonstrates a pronounced preventive effect against the development of CIPN, providing substantial symptomatic relief and quality of life improvements for patients undergoing chemotherapy. The administration of cryotherapy through the use of frozen gloves and socks, or continuous-flow cooling systems, optimally initiated 15 min prior to and concluded 15 min following chemotherapy, is recommended for achieving maximum therapeutic efficacy.
摘要：
目的：该研究调查了冷冻疗法在减轻化疗引起的周围神经病变（CIPN）中的疗效，化疗的不良反应，通常导致剂量减少或治疗中断。
方法：本研究注册于PROSPERO（CRD42023428936）。使用PubMed进行了文献检索，Embase,和Cochrane图书馆数据库。纳入研究冷冻疗法对CIPN影响的随机和非随机对照试验进行系统评价和荟萃分析。预防的主要结果是CIPN的发生率。
结果：我们确定了17项试验，涉及2,851例患者。总的来说,11项试验比较了冷冻治疗组和对照组的CIPN发生率。观察到化疗中点和结束时CIPN的发生率存在显着差异，风险比（RR）为0.23（95%置信区间[CI]=0.13至0.43）和0.54（95%CI=0.33至0.88），分别。冷冻疗法也显著降低了感觉CIPN的发生率，RR为0.67（95%CI=0.49至0.92）。此外,冷冻治疗显示妇科癌症患者CIPN的发生率显著降低(RR=0.24,95%CI=0.14~0.41).化疗后的整体生活质量评分明显良好（标准化平均差=1.43；95％CI=0.50至2.36），冷冻治疗可缓解神经性症状。
结论：冷冻疗法对CIPN的发展具有明显的预防作用，为接受化疗的患者提供实质性的症状缓解和生活质量改善。通过使用冷冻手套和袜子进行冷冻治疗，或连续流冷却系统，最佳在化疗前15分钟开始，并在化疗后15分钟结束，被推荐用于实现最大的治疗效果。
方法：本研究注册于PROSPERO（CRD42023428936）。使用PubMed进行了文献检索，Embase,和Cochrane图书馆数据库。纳入研究冷冻疗法对CIPN影响的随机和非随机对照试验进行系统评价和荟萃分析。预防的主要结果是CIPN的发生率。
结果：我们确定了17项试验，涉及2,851例患者。总的来说,11项试验比较了冷冻治疗组和对照组的CIPN发生率。观察到化疗中点和结束时CIPN的发生率存在显着差异，风险比（RR）为0.23（95%置信区间[CI]=0.13至0.43）和0.54（95%CI=0.33至0.88），分别。冷冻疗法也显著降低了感觉CIPN的发生率，RR为0.67（95%CI=0.49至0.92）。此外,冷冻治疗显示妇科癌症患者CIPN的发生率显著降低(RR=0.24,95%CI=0.14~0.41).化疗后的整体生活质量评分明显良好（标准化平均差=1.43；95％CI=0.50至2.36），冷冻治疗可缓解神经性症状。
结论：冷冻疗法对CIPN的发展具有明显的预防作用，为接受化疗的患者提供实质性的症状缓解和生活质量改善。通过使用冷冻手套和袜子进行冷冻治疗，或连续流冷却系统，最佳在化疗前15分钟开始，并在化疗后15分钟结束，被推荐用于实现最大的治疗效果。
